Airway epithelium-derived transforming growth factor-β is a regulator of fibroblast proliferation in both fibrotic and normal subjects
Summary Background In the healthy lung, airway epithelial cells (AEC) regulate fibroblast proliferation through release of soluble factors, such as prostaglandins and proteins. Fibroproliferative diseases and airway remodelling may result from an inadequate generation of suppressive factors by AEC o...
Saved in:
Published in | Clinical and experimental allergy Vol. 38; no. 8; pp. 1309 - 1317 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.08.2008
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Summary
Background
In the healthy lung, airway epithelial cells (AEC) regulate fibroblast proliferation through release of soluble factors, such as prostaglandins and proteins. Fibroproliferative diseases and airway remodelling may result from an inadequate generation of suppressive factors by AEC or the inability of fibroblasts to respond to them appropriately.
Objective
The aim of this study was to study the effect of primary human AEC on the proliferation of fibroblasts obtained from healthy and fibrotic lungs in an interactive cell culture model.
Results
Conditioned medium (CM) from 14 out of 16 AEC lines significantly inhibited proliferation of normal human lung fibroblasts by 51.2±6.0%. The proliferation of fibroblasts derived from patients with lung fibrosis was equally inhibited by CM of AEC. The inhibitory effect of AEC‐CM was completely reversed when fibroblasts were pre‐incubated with 2.5 μm indomethacin. Furthermore, primary human AEC, but not fibroblasts, secrete TGF‐β, and the inhibitory effect of the AEC‐CM was blocked by neutralizing anti‐TGF‐β antibodies.
Conclusion
These results demonstrate that AEC actively inhibit the proliferation of both normal and fibrotic fibroblasts via TGF‐β, which induces the prostaglandin E2 synthesis in fibroblasts. The data indicate that proliferative lung diseases may be treated using the epithelial cell as the target of medication. |
---|---|
Bibliography: | ArticleID:CEA3017 istex:263ABDA636BE04265EE3ADAAAFDBBD3409EE5654 ark:/67375/WNG-43DG4P2P-G ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0954-7894 1365-2222 1365-2222 |
DOI: | 10.1111/j.1365-2222.2008.03017.x |